Every year, tens of millions of MRI examinations are performed worldwide, and a significant proportion of them require the injection of a gadolinium-based contrast agent. This metal, indispensable for diagnosing many oncological, inflammatory, and vascular conditions, has long been regarded as a mere technical tool, with no consequences beyond the examination room. But what happens to gadolinium once it has been injected? Where does it go after passing through the patient’s body? And above all, can medical imaging continue to meet growing diagnostic needs while reducing its footprint on human health and the environment? These questions, long relegated to the background, are now asserting themselves with renewed urgency, as research documents the persistence of gadolinium in the body, in wastewater, and even in aquatic organisms far removed from hospitals.
A Useful Contrast Agent That Does Not Simply Disappear
Free gadolinium is highly toxic to the body: its ionic radius, close to that of calcium, allows it to interfere with numerous calcium-dependent cellular processes. This is why it is systematically chelated, meaning encapsulated within an organic molecular structure, before injection. Chelation strongly limits its direct toxicity, but it does not eliminate the problem: a fraction of the gadolinium can dissociate from its chelate, particularly in patients with impaired renal function, which led to the identification of nephrogenic systemic fibrosis in the 2000s. More broadly, gadolinium deposits have been documented in the brain, bones, and other tissues, including in patients with normal renal function, without the clinical impact of this retention being clearly established today.
Beyond the question of tissue retention, the environmental fate of gadolinium is of growing concern. Injected gadolinium is almost entirely eliminated via urinary excretion, generally within hours of the examination. Yet wastewater treatment plants are not designed to retain this type of compound: their high chemical stability, precisely what makes them safe for clinical use, also renders them resistant to conventional treatment processes. Gadolinium of anthropogenic origin, meaning directly linked to medical use, is now detectable in surface water, groundwater, and sometimes drinking water, with higher concentrations near large urban centers and hospitals performing MRI. Some studies have even found persistent contamination in marine filter-feeding organisms several years after a reduction in the most problematic point sources, a sign that this pollution is long-lasting.
Reducing at the Source: More Efficient Agents, Leaner Protocols
The first approach to reducing the gadolinium footprint consists of decreasing the amount injected without compromising diagnostic quality. A new generation of contrast agents, known as high-relaxivity agents, achieves a level of contrast enhancement comparable to that of established agents while halving the administered gadolinium dose. These molecules owe their efficacy to an optimized chemical structure that offers more exchange sites between gadolinium and surrounding water molecules, improving their enhancement power at an equivalent dose.
This dose reduction is accompanied by a broader reflection on responsible use. A significant proportion of contrast agents prepared in syringes remains unused after the examination and ends up incinerated with medical waste, without any recycling of the gadolinium they contain. Switching to multi-dose vials or excess-free injection systems could limit this waste. Furthermore, several clinical protocols, particularly for multiple sclerosis follow-up, have been revised to restrict repeated injections to truly diagnostically necessary timepoints, setting aside routine check-ups whose added value has proven limited.
Capturing Gadolinium Before It Enters the Environment
While source reduction is essential, it is not sufficient on its own to prevent all environmental dispersal: gadolinium administered at the lowest doses is still, ultimately, excreted in urine. This is why a second strategy explores targeted gadolinium capture directly at the hospital, before its dilution into municipal wastewater networks. The principle is straightforward: if the patient extends their hospital stay by approximately one hour after injection, during which a substantial proportion of the contrast agent is excreted, it becomes possible to collect this urine in dedicated containers rather than allowing it to enter conventional toilets. Once collected, this urine can be processed separately or stored for analysis, thereby preventing its uncontrolled discharge into the network.
This approach has the advantage of targeting the moment when gadolinium concentration in urine is at its highest, without requiring prolonged collection over several days, which would be far more burdensome for patients and therefore less well accepted. The challenge is not purely technical: it also involves measuring patients’ actual willingness to accept this additional constraint, modest but not negligible, in their care pathway. The adherence rate to this type of protocol is itself a valuable indicator of environmental sensitivity in a hospital population, capable of informing the feasibility of broader-scale deployment.
Alongside this upstream capture, advanced wastewater treatment methods are being explored to retain gadolinium that escapes these devices: membrane filtration, adsorption on activated carbon or specific resins, and advanced oxidation processes capable of degrading certain forms of chelates. These techniques, still costly in terms of energy and infrastructure at the municipal scale, are best used in combination rather than in isolation. Avenues for biological recycling of gadolinium via microorganisms capable of selectively sequestering lanthanides are also beginning to be studied as a promising complement to conventional physicochemical approaches.
The Other Path: Doing Without Gadolinium When Alternatives Exist
Beyond reducing and capturing already-injected gadolinium, the most radical approach is to dispense with it entirely when diagnostic alternatives exist. Several injection-free MRI sequences now provide functional or vascular information previously reserved for contrast-enhanced sequences, with performance levels that, for certain indications, approach those obtained after injection.
Among these techniques, Chemical Exchange Saturation Transfer (CEST) imaging occupies a particularly promising place. By exploiting the natural exchanges between protons of endogenous molecules, such as mobile proteins, and protons of water, this approach generates contrast reflecting the biochemical composition of tissues without any exogenous agent being injected. Applied, for example, to the follow-up of brain tumors, it offers a window onto the metabolic activity and protein density of tissue, with particular value for distinguishing tumor recurrence from a simple post-therapeutic reaction, a question that, with conventional enhanced imaging, sometimes remains ambiguous. The development of automated analysis pipelines and the standardization of acquisition protocols across centers currently represent the main barriers to be overcome before wider adoption of this technique in clinical routine.
Pseudo-continuous arterial spin labeling (pCASL) constitutes another contrast-free alternative, this time for cerebral perfusion imaging. This technique magnetically labels arterial blood water upstream of the territory to be explored, then tracks its distribution in the cerebral parenchyma, enabling estimation of tissue perfusion without any injection. It represents a particularly attractive option for patients requiring repeated follow-up, for whom the accumulation of gadolinium injections over the years constitutes a concern that is both clinical and environmental. Combined with other contrast-free functional approaches, it is part of a broader movement aimed at reserving gadolinium injection for situations where it provides truly demonstrated diagnostic added value, rather than using it by default or out of habit.
Artificial intelligence is reinforcing this dynamic of restrained use. Deep learning algorithms are now capable of synthesizing virtual contrast images from non-injected or low-dose sequences, drawing on protocols using only a fraction of the standard gadolinium dose.
Conclusion: A Shared Responsibility, at Every Level
Environmental responsibility in MRI is not reducible to a choice of molecule or a urine collection protocol: it engages the entire chain, from the mining of gadolinium to its final elimination in the environment, encompassing its formulation, administration, and monitoring. Current data show that there is no single solution, but a set of complementary levers: more effective contrast agents at reduced doses, better management of waste and unused stocks, targeted post-examination urine capture devices, more efficient wastewater treatment technologies, and above all, whenever clinically appropriate, the use of injection-free functional imaging techniques.
The question is no longer whether medical imaging must integrate this environmental dimension, but how to articulate it intelligently with the diagnostic imperative, without ever sacrificing the quality of care provided to patients.
Sources
Bendszus M, Laghi A, Munuera J, Tanenbaum LN, Taouli B, Thoeny HC. MRI Gadolinium-Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs. J Magn Reson Imaging. 2024 Nov;60(5):1774-1785. doi: 10.1002/jmri.29181. PMID: 38226697. https://pubmed.ncbi.nlm.nih.gov/38226697/
Zanardo M, Cozzi A, Cardani R, Renna LV, Pomati F, Asmundo L, Di Leo G, Sardanelli F. Reducing contrast agent residuals in hospital wastewater: the GREENWATER study protocol. Eur Radiol Exp. 2023 May 4;7(1):27. doi: 10.1186/s41747-023-00337-w. PMID: 37142839. https://pubmed.ncbi.nlm.nih.gov/37142839/
Long MR, Dayan NA, Xu M, Liao W, Gilad AA, DeLano MC. Gadolinium Pollution — A Future Forward Perspective on Human and Environmental Impact. Magn Reson Med. 2026 Mar;95(3):1660-1670. doi: 10.1002/mrm.70157. PMID: 41152142. https://pubmed.ncbi.nlm.nih.gov/41152142/
